Neptune Technologies Reports Fiscal 2009 Results - Record Revenue and Profitability Growth in Nutraceutical Business

    Financial Results: Three-Month Period ended February 28, 2009

    Sales Growth:
    -------------
    - Revenues for the three-month period ended February 28, 2009 totalled a
      record $3,772,000, a 31% increase compared to $2,875,000 for the three-
      month period ended February 29, 2008.

    Profitability Growth:
    ---------------------
    - EBITDA for the three-month period ended February 28, 2009 reached
      $888,000 which represents an increase of 155% compared to $348,000
      achieved during the three-month period ended February 29, 2008.

    Earnings Growth:
    ----------------
    - Net profit for the three-month period ended February 28, 2009 amounted
      to $71,000 or $0.002 per share, compared to a net loss of $886,000 or
      $0.024 per share, for the three-month period ended February 29, 2008.

    Financial Results: Nine-Month Period ended February 28, 2009

    Sales Growth:
    ------------
    - Revenues increased by 20.5% to $8,589,000, during the nine-month period
      ended February 28, 2009, from $7,129,000 achieved during the previous
      fiscal year nine-month period ended February 29, 2008.

    Profitability Growth:
    ---------------------
    - Consolidated EBITDA for the nine-month period ended February 28, 2009
      represents $337,000 compared to $750,000 obtained during the nine-month
      period ended February 29, 2008.

    - EBITDA for Neptune Nutraceutical, excluding Acasti Pharma et
      NeuroBioPharm, for the nine-month period ended February 28, 2009
      amounted to $1,238,000 which represents an increase of 65% compared to
      the nine-month period ended February 29, 3008.

    Earnings Growth:
    ----------------
    - Net loss decreased by $1,611,000 and represents $1,889,000 or $0.05 per
      share which is an improvement of 46% for the nine-month period ended
      February 28, 2009 compared to a net loss of $3,500,000 or $0.095 per
      share, for the previous fiscal nine-month period. This improvement is
      mainly due to an increase in productivity as well as an increase of
      gross margins reflected in the costs of sales and operating expenses.

    Cash Position
    -------------
    - The Company believes that Neptune's cash position and financial
      performance provide for a self-sustainable profitable nutraceutical
      business. As of February 28, 2009, Neptune's cash and cash equivalents
      totalled $4,154,000.

    Neptune announces amendments to the Company and the Acasti stock options
    plans

    Neptune announces that on April 29, 2009, its subsidiary Acasti Pharma
amended the existing stock option plan for directors, officers, employees and
consultants initially adopted on October 8, 2008 (the "Acasti Plan"), as
required by the TSX Venture Exchange. The Acasti Plan now allows the board of
directors of Acasti to grant options for Acasti Class A shares representing up
to 10% of the outstanding issued Acasti shares subject to a maximum of
1,530,000 Acasti options.
    On April 29, 2009, Neptune also amended its stock option plan ("Neptune
Plan") to provide that each option granted under the Acasti Plan will reduce
by one the number of shares available for further issuance under the Neptune
Plan and each option cancelled under the Acasti Plan will increase by one, the
number of shares available under the Neptune plan, until the date on which the
shares of Acasti qualify as "exchange-traded securities" under applicable
securities laws and regulations.
    The Acasti Plan and annual grant of options to purchase Acasti Class A
shares must be approved each year by disinterested shareholders of Neptune at
its annual general meeting. Accordingly, at the annual general meeting of the
shareholders to be held on June 9, 2009, the disinterested shareholders of
Neptune will be asked to approve the Acasti Plan and the grant of 850,000
stock options to various Acasti directors, officers and employees made on
October 8, 2008.

    (1) Earnings before Interest, Taxes, Depreciation, and Amortization